Chronic migraine (CM) Nervous System Diseases Chronic migraine (CM)
Conditions
Interventions
Participants receive verum acupuncture and placebo medicine in the treatment group, while participants in the control group are treated with sham acupuncture and medicine (topiramate). All participant
Yangming headache (LI-ST): LI4 (Hegu), ST44 (Neiting)
Taiyang headache (SI-BL): BL60 (Kunlun), SI3 (Houxi)
Jueyin headache (PC-LR): LR3 (Taichong), GB40 (Qiuxu)
Needles are inserted in an appropriate
Sponsors
Beijing Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosed as chronic migraine according to the diagnostic criteria specified by the International Classification of Headache Disorders(International Classification of Headache Disorders-Third edition (beta version) [ICHD-?ß]) 2. Aged between 18 and 65 years old 3. No prophylaxis treatments with acupuncture or drugs in the past 3 months 4. Written informed consent provided
Exclusion criteria
Exclusion criteria: 1. Tension-type headache, cluster headache, and other primary headaches 2. Relatively severe systemic diseases(cardiovascular disease, acute infectious disease, hematopathy,endocrinopathy, allergy, and methysis) 3. Headache caused by otorhinolaryngology diseases or intracranial pathological changes 4. Secondary headache and other neurological diseases 5. Pregnancy, lactation, or insufficient contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Monthly number of headache days (any intensity) is measured using the headache diary at baseline period (4 weeks before the beginning of treatment) and 12 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Number of days with acute headache medications is measured using headache diary at baseline period (4 weeks before the beginning of treatment) and 12 weeks. 2. Migraine Disability is measured using the MIDAS score at baseline, 12 weeks, and 24 weeks. 3. Migraine-Specific Quality-of-Life Questionnaire/Headache impact test measured using the MSQ/HIT6 questionnaire at baseline, 12 weeks, and 24 weeks. 4. Anxiety is measured using the STAI/BDI-II questionnaires at baseline, 12 weeks, and 24 weeks. | — |
Countries
China
Contacts
Public ContactBin;Lu Li;Liu
;
Outcome results
None listed